Anne Floquet

18.1k total citations
170 papers, 3.3k citations indexed

About

Anne Floquet is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Anne Floquet has authored 170 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Reproductive Medicine, 70 papers in Oncology and 47 papers in Obstetrics and Gynecology. Recurrent topics in Anne Floquet's work include Ovarian cancer diagnosis and treatment (95 papers), Endometrial and Cervical Cancer Treatments (38 papers) and PARP inhibition in cancer therapy (35 papers). Anne Floquet is often cited by papers focused on Ovarian cancer diagnosis and treatment (95 papers), Endometrial and Cervical Cancer Treatments (38 papers) and PARP inhibition in cancer therapy (35 papers). Anne Floquet collaborates with scholars based in France, Italy and United States. Anne Floquet's co-authors include Gaëtan MacGrogan, L. Mauriac, M. Durand, A. Avril, Marc Debled, F. Bonichon, Jean-Marie Dilhuydy, Sabrina Croce, Frédéric Guyon and Isabelle Ray‐Coquard and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Anne Floquet

159 papers receiving 3.2k citations

Peers

Countries citing papers authored by Anne Floquet

Since Specialization

Citations

This map shows the geographic impact of Anne Floquet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Floquet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Floquet more than expected).

Fields of papers citing papers by Anne Floquet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Floquet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Floquet. The network helps show where Anne Floquet may publish in the future.

Co-authorship network of co-authors of Anne Floquet

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Floquet. A scholar is included among the top collaborators of Anne Floquet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Floquet. Anne Floquet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study 2023 ·Drugs - Real World Outcomes ·(unknown), Laurence Gladieff, Fanny Le Du, Dominique Berton, C. Bonnard, (unknown), (unknown), (unknown), (unknown), Gilles Freyer, Anne Floquet, (unknown), Maria Kfoury	2
2	Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study 2022 ·The Lancet Healthy Longevity ·Claire Falandry, Fanny Pommeret, Laurence Gladieff, Fabien Tinquaut, Domenica Lorusso, Marie‐Ange Mouret‐Reynier, Véronique D’Hondt, (unknown), Anne Floquet, Sophie Abadie‐Lacourtoisie, Pierre-Emmanuel Brachet, Laëtitia Stefani, Frédérique Rousseau, Jean‐Sébastien Frenel, Francesco Del Piano, Marja Komulainen, (unknown), Olivier Trédan, Éric Pujade-Lauraine, Gilles Freyer	7
3	528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant? 2022 ·Annals of Oncology ·(unknown), Maria Kfoury, Domenica Lorusso, Anne Floquet, Jole Ventriglia, (unknown), (unknown), Romain Rivoirard, (unknown), Laure Favier, Benoît You, Dominique Berton-Rigaud, Thibault De La Motte Rouge, Luigi Mansi, Cyril Abdeddaim, (unknown), Laurence Lecomte, (unknown), Cécile Dalban, Isabelle Laure Ray-Coquard	3
4	517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial 2022 ·Annals of Oncology ·Paul DiSilvestro, Susana Banerjee, N. Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Andrew Martin, (unknown), (unknown), Cara Mathews, (unknown), Elizabeth Lowe, (unknown)	5
5	Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer 2022 ·International Journal of Gynecological Cancer ·Sarah Bétrian, Martina Aida Ángeles, (unknown), Bastien Cabarrou, Marion Deslandres, Gwénaël Ferron, Eliane Mery-Lamarche, Anne Floquet, Frédéric Guyon, Assumpció Pérez‐Benavente, Emanuela Spagnolo, (unknown), Laurence Gladieff, Alicia Hernández, Alejandra Martínez	8
6	733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study 2021 ·Annals of Oncology ·Gilles Freyer, Anne Floquet, Olivier Trédan, Carole Langlois‐Jacques, Frédèric Selle, Cyril Abdeddaim, Alexandra Léary, Coraline Dubot, Michel Fabbro, Laurence Gladieff, Christophe Sajous	6
7	827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc) 2020 ·Annals of Oncology ·(unknown), Laurence Gladieff, Fanny Le Du, (unknown), Dominique Berton-Rigaud, C. Bonnard, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Céline Gavoille, Gilles Freyer, Anne Floquet, (unknown), Maria Kfoury	1
8	811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 2020 ·Annals of Oncology ·Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro	47
9	LBA67 TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas 2020 ·Annals of Oncology ·Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, Alban Bessede, Michèle Kind, (unknown), M. Pulido, Sophie Cousin, Kévin Bourcier, Sabrina Albert, (unknown), Camille Chakiba, (unknown), Anne Floquet, Sabrina Croce, Simone Mathoulin‐Pélissier, Raul Perret, Jean‐Yves Blay, Antoîne Italiano	5
10	A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113) 2020 ·International Journal of Gynecological Cancer ·Isabelle Ray‐Coquard, Helen Hatcher, Emmanuelle Bompas, Antonio Casado, (unknown), Nicolás Isambert, Paolo G. Casali, Sarah Pratap, Dan Stark, Claudia Valverde, Anjana Anand, Manon Huizing, Anne Floquet, Lars H. Lindner, Bárbara Hermes, Beatrice Seddon, Corneel Coens, Robin L. Jones, Nick Reed	3
11	The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas 2019 ·Clinical Cancer Research ·Sabrina Croce, Tom Lesluyes, Carine Valle, Loubna Mhamdi, (unknown), Gaëlle Pérot, Eberhard Stoeckle, Jean‐Christophe Noël, (unknown), Mojgan Devouassoux‐Shisheboran, Denis Querleu, Frédéric Guyon, Anne Floquet, Camille Chakiba, Laétitia Mayeur, (unknown), Gaëtan MacGrogan, Isabelle Soubeyran, Sophie Le Guellec, Frédéric Chibon	15
12	Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial 2018 ·Annals of Oncology ·Michael Friedländer, (unknown), N. Colombo, Giovanni Scambia, (unknown), Ana Oaknin, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, (unknown), Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, (unknown), (unknown), (unknown), Ralph Bloomfield, Paul DiSilvestro	1
13	Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy 2013 ·Journal of Clinical Oncology ·Stéphanie Hoppe, M. Rainfray, Marianne Fonck, (unknown), Jean‐Frédéric Blanc, J. Ceccaldi, C. Mertens, C. Blanc-Bisson, Y. Imbert, Laurent Cany, (unknown), Jérôme Dauba, Nadine Houédé, Carine Bellera, Anne Floquet, (unknown), Alain Ravaud, Camille Chakiba, Simone Mathoulin‐Pélissier, Pierre Soubeyran	174
14	Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer 2012 ·Journal of Clinical Oncology ·Pierre Soubeyran, Marianne Fonck, C. Blanc-Bisson, Jean‐Frédéric Blanc, J. Ceccaldi, C. Mertens, Y. Imbert, Laurent Cany, (unknown), Jérôme Dauba, Francis Andriamampionona, Nadine Houédé, Anne Floquet, François Chomy, Véronique Brouste, Alain Ravaud, Carine Bellera, M. Rainfray	305
15	Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials 2003 ·UCL Discovery (University College London) ·Pierluigi Benedetti Panici, Adriana Bermúdez, (unknown), (unknown), (unknown), (unknown), (unknown), Anne Floquet, Charles A. Nelson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Luís Souhami, Kolbein Sundfør, P. S. Symonds, (unknown), Stefano Greggi, Mahesh Parmar, (unknown), (unknown), (unknown), (unknown)	6
16	Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy 2003 ·International Journal of Gynecological Cancer ·Martine Piccart, Anne Floquet, Giovanna Scarfone, Pax H.B. Willemse, Janusz Emerich, I. Vergote, L. Giurgea, C. Coens, Ahmad Awada, Jan B. Vermorken	83
17	Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women 2002 ·Annals of Oncology ·L. Mauriac, Marc Debled, M. Durand, Anne Floquet, (unknown), Corinne Dagada, Nathalie Trufflandier, Gaëtan MacGrogan	23
18	Paysans, Etat et ONG au Bénin 1999 ·Pierre‐Yves Le Meur, Thomas Bierschenk, Anne Floquet	5
19	[Hansen's neuritis in the form of pseudysyringomyelia. Clinical, diagnostic and therapeutic consideration a propos of 3 cases]. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Juliano Vilaverde Schmitt, D Barrucand, J Floquet, Anne Floquet, (unknown)	1
20	Névrite hansénienne à forme pseudosyringomyélique. Considérations cliniques, diagnostiques et thérapeutiques à propos de trois cas 1976 ·Revue Neurologique ·Jochen Schmitt, D Barrucand, J Floquet, Anne Floquet, Christian Schmidt	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact